These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 10738106

  • 1. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E.
    Cancer Lett; 2000 Apr 14; 151(2):127-32. PubMed ID: 10738106
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E.
    Oncogene; 2012 Nov 01; 31(44):4718-24. PubMed ID: 22266871
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E.
    Int J Oncol; 2000 Mar 01; 16(3):555-60. PubMed ID: 10675489
    [Abstract] [Full Text] [Related]

  • 4. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
    Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F.
    Oncol Rep; 2000 Mar 01; 7(5):1123-8. PubMed ID: 10948350
    [Abstract] [Full Text] [Related]

  • 5. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
    Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.
    Biochem Pharmacol; 2000 Dec 01; 60(11):1611-9. PubMed ID: 11077043
    [Abstract] [Full Text] [Related]

  • 6. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R, Taron M, Camps C, López-Vivanco G.
    Drugs Today (Barc); 2003 Oct 01; 39(10):775-86. PubMed ID: 14668933
    [Abstract] [Full Text] [Related]

  • 7. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
    Chen ZP, Malapetsa A, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Panasci LC.
    Ai Zheng; 2002 Mar 01; 21(3):233-9. PubMed ID: 12451985
    [Abstract] [Full Text] [Related]

  • 8. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas.
    Liang BC, Ross DA, Reed E.
    J Neurooncol; 1995 Oct 01; 26(1):17-23. PubMed ID: 8583241
    [Abstract] [Full Text] [Related]

  • 9. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
    Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC.
    Anticancer Drugs; 2002 Jun 01; 13(5):511-9. PubMed ID: 12045463
    [Abstract] [Full Text] [Related]

  • 10. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.
    Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L.
    Cancer Res; 2002 Oct 01; 62(19):5457-62. PubMed ID: 12359753
    [Abstract] [Full Text] [Related]

  • 11. MZF1 possesses a repressively regulatory function in ERCC1 expression.
    Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ.
    Biochem Pharmacol; 2006 Mar 14; 71(6):761-71. PubMed ID: 16426580
    [Abstract] [Full Text] [Related]

  • 12. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
    Cancer Res; 2003 Mar 15; 63(6):1311-6. PubMed ID: 12649192
    [Abstract] [Full Text] [Related]

  • 13. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W, Wu FX, Wang Q, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr 15; 47(4):286-91. PubMed ID: 22781116
    [Abstract] [Full Text] [Related]

  • 14. Computer based analyses of the 5'-flanking regions of selected genes involved in the nucleotide excision repair complex.
    Zhong X, Thornton K, Reed E.
    Int J Oncol; 2000 Aug 15; 17(2):375-80. PubMed ID: 10891549
    [Abstract] [Full Text] [Related]

  • 15. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
    Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.
    J Clin Invest; 1994 Aug 15; 94(2):703-8. PubMed ID: 8040325
    [Abstract] [Full Text] [Related]

  • 16. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
    Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL.
    Clin Cancer Res; 2003 Nov 01; 9(14):5299-305. PubMed ID: 14614013
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.
    Cancer; 2012 Feb 01; 118(3):689-97. PubMed ID: 21751198
    [Abstract] [Full Text] [Related]

  • 19. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.
    Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E.
    J Natl Cancer Inst; 1992 Oct 07; 84(19):1512-7. PubMed ID: 1433335
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.